ATO Injection 10 mg/vial contains Arsenic Trioxide, a potent antineoplastic agent used primarily in the treatment of acute promyelocytic leukemia (APL). It is a highly specialized chemotherapy drug that works by inducing cancer cell differentiation and apoptosis. ATO Injection is administered intravenously under strict hospital supervision due to its narrow therapeutic index and potential toxicity.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Active Ingredient: Arsenic Trioxide 10 mg per vial

Mechanism of Action

Arsenic Trioxide acts through multiple mechanisms in leukemia cells. It promotes differentiation of malignant promyelocytes and induces programmed cell death (apoptosis). Additionally, it degrades the PML-RARα fusion protein characteristic of acute promyelocytic leukemia, helping restore normal cellular maturation and controlling disease progression.

Indications

ATO Injection is indicated for:

• Acute promyelocytic leukemia (APL), particularly in:
  • Relapsed or refractory cases
  • Newly diagnosed low-to-intermediate risk patients (in combination therapy)
• Use in combination with all-trans retinoic acid (ATRA) in certain treatment protocols

Dosage and Administration

• Administered intravenously in a hospital setting only
• Dose and schedule depend on treatment phase and patient condition
• Infusion must be given slowly under close medical supervision
• Requires careful monitoring of cardiac and electrolyte status during therapy
• Treatment is typically conducted in cycles as directed by an oncologist

Benefits

• Highly effective in treating acute promyelocytic leukemia
• Induces remission in relapsed or refractory APL cases
• Works synergistically with ATRA in combination therapy
• Improves long-term survival outcomes in appropriate patients
• Targeted action on malignant promyelocytes

Possible Side Effects

Common side effects may include:

• Nausea and vomiting
• Fatigue
• Fever
• Abdominal pain
• Edema

Serious but potentially life-threatening side effects:

• QT interval prolongation and cardiac arrhythmias
• Differentiation syndrome (fever, respiratory distress, weight gain)
• Electrolyte imbalance (hypokalemia, hypomagnesemia)
• Hepatotoxicity
• Severe allergic reactions

Immediate medical intervention is required if serious adverse effects occur.

Precautions and Warnings

• Requires continuous ECG and electrolyte monitoring during treatment
• Use cautiously in patients with cardiac disease or arrhythmia risk
• Correct electrolyte abnormalities before and during therapy
• Not recommended during pregnancy unless absolutely necessary
• Administer only in specialized oncology settings

Drug Interactions

• Increased risk of QT prolongation with other QT-prolonging drugs
• Caution with diuretics causing electrolyte imbalance
• Avoid concurrent use with certain antiarrhythmic medications
• Inform physician of all medications prior to treatment

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage

• Store below 25°C
• Protect from light
• Do not freeze
• Keep out of reach of children
• Use only as prepared by healthcare professionals

Conclusion

ATO Injection 10 mg/vial (Arsenic Trioxide) is a highly effective targeted chemotherapy agent for acute promyelocytic leukemia. Due to its potent activity and potential risks, it must be administered under strict medical supervision with careful monitoring to ensure safety and optimal therapeutic outcomes.